Apixaban: an emerging oral factor Xa inhibitor-Reference-Cited by-同舟云学术

Apixaban: an emerging oral factor Xa inhibitor

Published:2009-11-18 Issue:1 Volume:29 Page:141-146
ISSN:0929-5305
Container-title:Journal of Thrombosis and Thrombolysis
language:en
Short-container-title:J Thromb Thrombolysis

Author:

Roser-Jones Christopher,Becker Richard C.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,Hematology

Link

http://link.springer.com/content/pdf/10.1007/s11239-009-0421-4.pdf

Reference16 articles.

1. Eriksson BI et al (2008) Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost 6(3):457–463

2. Luettgen JM et al (2006) In vitro evaluation of apixaban, a novel, potent, selective and orally bioavailable factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108(11):4130

3. Jiang X et al (2009) Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost 101(4):780–782

4. Raghavan N et al (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37(1):74–81

5. He K et al (2006) Preclinical pharmacokinetic and metabolism of apixaban, a potent and selective factor Xa inhibitor. Blood (ASH Annual Meeting Abstracts) 108(11):910

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An Iron–Mesoionic Carbene Complex for Catalytic Intramolecular C–H Amination Utilizing Organic Azides;Journal of the American Chemical Society;2021-11-28

2. Comparative Incidence of Postoperative Hemorrhage in Vitreoretinal Surgery in Patients on Anti-Coagulants;Ophthalmic Surgery, Lasers and Imaging Retina;2021-07

3. Design of Small-Molecule Active-Site Inhibitors of the S1A Family Proteases as Procoagulant and Anticoagulant Drugs;Journal of Medicinal Chemistry;2017-10-26

4. Hematoma Expansion Following Intracerebral Hemorrhage: Mechanisms Targeting the Coagulation Cascade and Platelet Activation;Current Drug Targets;2017-08-24

5. Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism;Hematology/Oncology Clinics of North America;2016-10